Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Courtney D. DiNardo et al.|Blood|2017Cited by 1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Eytan M. Stein et al.|New England Journal of Medicine|2018Cited by 1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.Robert H. Collins, John Nemunaitis, Nadine Ognoskie et al.|Journal of Clinical Oncology|1997Cited by 1.3k
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P. Shah, Kristina M. Gregory, Ravi Bhatia et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 116
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Jeffrey Tyner, Beth Wilmot et al.|Blood|2019Cited by 84